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Abstract: We designed two Phase I studies that assessed healthy volunteers in order to evaluate 
the safety and to optimize the dosing of the combination of the drugs isosorbide dinitrate, a nitric 
oxide donor, and ibuprofen, a nonsteroidal antiinflammatory drug. We designed these studies 
with the aim of designing a Phase II trial to evaluate the drugs’ efficacy in patients affected 
by Duchenne muscular dystrophy. For the first trial, ISOFEN1, a single-dose, randomized-
sequence, open-label, active control, three-treatment cross-over study, was aimed at comparing 
the pharmacokinetics of ibuprofen 200 mg and isosorbide dinitrate 20 mg when given alone 
and concomitantly. The pharmacokinetics of ibuprofen given alone versus ibuprofen given 
concomitantly with isosorbide dinitrate were similar, as documented by the lack of statistically 
significant differences in the main drug’s pharmacokinetic parameters (time to maximal con-
centration [T
max
], maximal concentration [C
max
], area under the curve [AUC]
0–t
, and AUC
0–∞). 
Similarly, we found that the coadministration of ibuprofen did not significantly affect the 
pharmacokinetics of isosorbide dinitrate. No issues of safety were detected. The second trial, 
ISOFEN2, was a single-site, dose titration study that was designed to select the maximum toler-
ated dose for isosorbide dinitrate when coadministered with ibuprofen. Eighteen out of the 19 
enrolled subjects tolerated the treatment well, and they completed the study at the highest dose 
of isosorbide dinitrate applied (80 mg/day). One subject voluntarily decided to reduce the dose 
of isosorbide dinitrate from 80 mg to 60 mg. The treatment-related adverse events recorded 
during the study were, for the large majority, episodes of headache that remitted spontaneously 
in 0.5–1 hour – a known side effect of isosorbide dinitrate. These studies demonstrate that the 
combination of isosorbide dinitrate and ibuprofen does not lead to pharmacokinetic interactions 
between the two drugs; they also demonstrate that the combination of isosorbide dinitrate and 
ibuprofen has optimal tolerability and safety profiles that are similar to those previously reported 
for isosorbide dinitrate and ibuprofen given alone.
Keywords: coadministration, pharmacokinetic profile, adverse events, ibuprofen, isosorbide 
dinitrate
Introduction
Duchenne muscular dystrophy (DMD) is a severe generic disease that causes progres-
sive wasting of the skeletal muscle accompanied by severe local inflammation, and 
this invariably leads to death in early adulthood.1 At present, there is no resolutive 
therapy, and the current therapeutic protocols are still based on the administration 
of corticosteroids, which provide some delays in the progression of the disease, but 
they are also associated with severe side effects.1 Therapies that substitute corti-
costeroids, or that at least may act as corticosteroid-sparing drugs, are thus being 
actively pursued.2,3
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While genetic and stem cell approaches appear to offer 
significant steps toward a resolute therapy, they are expen-
sive and are still not readily available, as the results of the 
last clinical trials indicate.4–6 In addition, they target only 
specific subsets of patients (for example, about 13% in the 
case of exon 51 skipping).7 “Classical” pharmacological 
approaches, while not aiming to cure the disease, do appear 
to be attractive options and are of significant value for a 
variety of reasons. Drugs may slow disease progression and 
they may have broad applicability, as they are not selective 
for a specific gene mutation. In addition, they may be used 
in combined approaches with gene/cell therapies to enhance 
the overall therapeutic efficacy, and they may possibly be 
substituted for corticosteroids, or they may at least lead to 
corticosteroid-sparing regimens.
Possible successful pharmacological strategies are those 
based on either individual drugs or drug combinations that 
address the downstream pathogenic effects of dystrophin 
deficiency, which ultimately leads to muscle loss.
Two key pathological events in DMD appear to be 
particularly susceptible to pharmacological interventions: 
local inflammation, which is recognized as playing a role 
in fiber destruction and in the progression of the disease,8 
hence the beneficial effect of corticosteroids; and reduc-
tions in the generation of nitric oxide (NO), which leads to 
muscle fatigue and a reduced bioenergetics capacity, and 
which plays a role in the neurogenic defects associated with 
the disease.9–11 Indeed, endogenous NO generation protects 
muscle from damage during contractile activity12–14 and it 
enhances its repair.15–19
Studies in the mdx and α-sarcoglycan null mouse models 
of muscular dystrophy showed that exposure to a combination 
of NO donation and nonsteroidal antiinflammatory activities 
has long-term therapeutic effects on disease progression and 
muscle function.20–26 Among the possibilities we tested, the 
combination of isosorbide dinitrate (ISO), a NO donating 
molecule, and ibuprofen, a nonsteroidal antiinflammatory 
drug – which are licensed for use in humans – was found 
to be of significant therapeutic effect.25,26 In particular, this 
therapy reduced muscle inflammation, necrosis, and fibrosis, 
and ameliorated mouse performance in the free wheel and 
treadmill tests that measure voluntary movement and resis-
tance to exercise, respectively.25,26 Both the morphostructural 
and functional beneficial effects of the therapy persisted over 
the 12 months of experimental treatment.
The safety and tolerability of the coadministration of ISO 
and ibuprofen in dystrophic patients were confirmed in an 
open-label, single-centre pilot study.27
These data open novel perspectives for the use of NO-
based approaches in DMD and support the design of a new 
clinical trial to evaluate their efficacy.
Based on the above premises, we decided to design two 
Phase I studies conducted with healthy volunteers to optimize 
dosing of the combination of ISO and ibuprofen to be subse-
quently used in efficacy trials. The first trial (ISOFEN1) was 
designed to define, through a pharmacokinetic approach, the 
drug combination’s bioavailability in healthy volunteers when 
compared with that of the single active principles.
The second trial (ISOFEN2) was designed to define the 
maximum tolerated dose of ISO in combination with ibu-
profen, and to assess the safety of the combined treatment 
in terms of adverse events (AEs) and variations of blood 
pressure (BP) during the trial.
Materials and methods
isOFen – study planning
ISOFEN1 was a single-dose, randomized-sequence, open-
label, active control, three-treatment cross-over study 
aimed at comparing the pharmacokinetics of ibuprofen 
(200 mg) and ISO (20 mg) when given alone and con-
comitantly in healthy volunteers (EudraCT number 2011-
002881-19). ISOFEN2 was a single-site, dose titration 
study carried out in healthy male volunteers, which was 
designed to select the maximum tolerated dose for ISO 
when coadministered with ibuprofen (EudraCT number 
2012-001193-29). 
Both trials were approved by the Competent Authorities 
(Istituto Superiore di Sanità, Rome, Italy and the Ethical 
Committee of the Luigi Sacco University Hospital, Milan, 
Italy) and performed at the Center for Phase I Clinical 
Studies of the Luigi Sacco University Hospital in accordance 
with the current revision of the Declaration of Helsinki. All 
of the subjects were recruited from the Healthy-Volunteer’s 
Database of the Luigi Sacco University Hospital, and each 
gave their written informed consent to participate in the 
study.
isOFen1 – study design
For the screening visit (V1), subjects were admitted into 
the hospital at 7 am in a fasting condition, and they had 
been previously instructed not to eat or drink anything 
(except water, which was allowed up to 1 hour before the 
study initiation) for approximately 8 hours prior to each 
scheduled visit. They were then allowed to eat standard 
meals 4 hours after drug administration during the phar-
macokinetic visit.
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At visit two (V2), subjects satisfying all the inclusion/
exclusion criteria were randomized to one of the three treat-
ment sequences. Trial treatment medications were ibuprofen 
(200 mg) or ISO (20 mg), or ibuprofen (200 mg) plus ISO (20 
mg) given concomitantly. All treatments were given as single 
oral doses. Other treatments were given in visits three and 
four (V3 and V4), according to the sequence randomization 
scheme with a wash out of at least 3 days between the periods, 
according to the reported half-lives of the study drugs.28,29 
Detailed pharmacokinetic evaluations were performed dur-
ing each of the treatment visits (V2–V4), together with the 
assessment of vital signs, pulse rate, and BP.
isOFen1 – tolerability assessments
AEs were evaluated before the administration of each dose 
of the study drug and at the time of each blood draw, based 
on direct observation and spontaneous reports. Vital signs 
(BP and heart rate) were measured 1 hour and 3 hours after 
the study drug intake. All undesirable signs, symptoms, or 
medical conditions occurring after the start of the study were 
recorded individually on case report forms by the investiga-
tors, separately. BP was measured with an aneroid sphyg-
momanometer in the right arm, and heart rate was measured 
manually on the radial artery.
isOFen1 – pharmacokinetic analysis
During each pharmacokinetic assessment, subjects had free 
access to water. Standard meals were provided 4 hours after 
drug administration. A venous cannula was placed in a forearm 
vein, and a 4 mL blood sample was drawn into lithium heparin 
tubes. Blood samples were drawn immediately before the study 
drug intake (time 0), and at 30 minutes, 60  minutes, 90 minutes, 
120 minutes, 150 minutes, 180 minutes, 210 minutes, 
240 minutes, and 5 hours, 6 hours, 8 hours, 10 hours, and 12 
hours after drug administration. Blood samples were centri-
fuged within 15 minutes of collection at 2,500× g at 4°C for 10 
minutes. Plasma samples were then stored at –20°C in stopped 
polypropylene tubes until analysis.
Plasma ibuprofen concentrations were assessed using 
a high-performance liquid chromatography method 
with diode array detection. The method is linear from 
0.5–100 mg/L, with imprecision and inaccuracy below 
10%. Plasma isosorbide concentrations were quantified 
by high-performance liquid chromatography coupled with 
tandem mass spectrometry. The method is linear over the 
concentration range of 1.0–1,000 ng/mL, with imprecision 
and inaccuracy below 15%. Both chromatographic methods 
have been previously developed and validated30–33 according 
to the United States Food and Drug Administration’s guide-
lines for bioanalytical method validation.34
The following drug pharmacokinetic parameters were 
determined for each subject: maximal concentration (C
max
) 
and its time (T
max
), as read directly from the data; the area 
under the curve (AUC)
0–12
, as determined by the trapezoidal 
rule; elimination rate (k
elimin
), as calculated by least squares 
regression analysis of terminal log–linear portions of the 
plasma concentration–time profile; t
1/2
 as Ln2/k
elimin
; and 
AUC
0–∞ as the sum of AUC0–12 and the extrapolated area 
given by the quotient of the last measured concentration 
and k
elimin
.
isOFen2 – study design
The study consisted of a screening visit (V1), a treatment 
phase (V2–V5), and a final visit (V6). At V2, the subjects 
satisfying the inclusion/exclusion criteria started treatment 
with the study drugs at the lowest dose, which was 200 mg 
once daily (qd) of ibuprofen and 20 mg qd of ISO for 1 week. 
ISO was titrated up to 80 mg qd (with 20 mg increment per 
visit) in subjects with diastolic BP (DBP) .60 mmHg; the 
dose of ibuprofen was maintained at 200 mg qd throughout 
the duration of the study. In subjects with DBP ,60 mmHg 
or symptomatic hypotension, the dose of ISO was maintained 
at the current tolerated dosage and up-titrated at the following 
visit or maintained as such, depending on the DBP values 
(Figure 1).
The subjects arrived at the Center for Phase I clinical 
studies in the morning between 7 am and 10 am after fast-
ing for 8 hours overnight, and before the administration of 
the study drugs. The subjects were confined in the center 
for at least 3 hours following drug intake. In order to limit 
potential ibuprofen-related gastrointestinal complications, 
the proton pump inhibitor pantoprazole 20 mg/day was added 
throughout the study period. A complete physical examina-
tion with the assessment of vital signs, pulse rate, and BP, 
with particular attention to the DBP, was performed during 
each visit, before the choice of the new treatment dosage 
according to the protocol.
At the end of the visit, the drugs were dispensed in blisters 
containing the number of tablets to be used until the next 
visit, and instructions were provided to take the study drugs 
and the rescue therapy every day in the morning.
isOFen2 – tolerability assessments
The subjects were continuously monitored by the investiga-
tors for AEs. These were evaluated before the administration 
of each dose of the study drug, based on direct observation 
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and spontaneous reports. Vital signs (BP and heart rate) 
were measured at predose, 30 minutes, 1 hour, and 3 hours 
post-drug intake, and all undesirable signs, symptoms, or 
medical conditions occurring after the start of the study were 
recorded individually on case report forms by the investiga-
tors, separately. We considered the maximum tolerated ISO 
dose as the one that, when given with ibuprofen at 200 mg qd, 
was well tolerated by at least 85% of the enrolled subjects.
statistical analysis
Demographic characteristics were described according to 
qualitative or quantitative data. The assessment of safety was 
based primarily on the frequency of AEs, laboratory abnor-
malities, and serious AEs. In agreement with the European 
Medicines Agency’s (EMA’s) Guideline on the Investigation 
of Bioequivalence,35 the assessment of bioequivalence was 
based upon 90% confidence intervals (CIs) for the ratio of 
the population geometric means (drug alone/combined treat-
ment). The pharmacokinetic parameters under consideration 
(ie, AUC
0–t
, AUC
0–∞, Cmax, Tmax) were analyzed using analysis 
of variance (ANOVA), and data were transformed prior to 
analysis using a logarithmic transformation. A CI for the 
difference between treatments on the log-transformed scale 
was obtained from the ANOVA model. The CI was then 
back-transformed to obtain the desired CI for the ratio on 
the original scale. For these parameters, the 90% CI for the 
ratio of the test and reference products should be contained 
within the acceptance interval of 0.80–1.25.
Results
isOFen1 – subjects’ characteristics
Twelve healthy Caucasian male volunteers were screened, 
randomly assigned to one of the three sequence treatments, 
and included in the pharmacokinetics study. Baseline char-
acteristics of the enrolled subjects are given in Table 1. 
All subjects were Caucasians and the large majority were 
nonsmokers. The mean age was 23±2 years, and the mean 
body mass index was 22.62±2.58 kg/m2.
isOFen1 – tolerability
All enrolled subjects completed the study. Safety assess-
ments, including hematochemical analyses, vital signs, and 
cardiac and respiratory evaluations showed no differences 
between the beginning and the end of the study (Table 2). A 
total of 15 AEs were reported during the study. Of these, 13 
were assessed as treatment-related. In particular, all subjects 
experienced episodes of mild headache, remitting spontane-
ously in 0.5–1 hours – a known side effect of ISO. No AEs led 
to discontinuation, and no AEs that were defined as serious 
occurred during the study.
Visit
Screening Treatment
1 2 3 4 5 6 final
−30/0 1 5–7 10–14
IBU 200 mg +
ISO 60 mg
IBU 200 mg +
ISO 80 mg
IBU 200 mg +
ISO 40 mg
If DBP ≥60 mmHg
If DBP <60 mmHg If DBP <60 mmHg If DBP >60 mmHg
Increase dose
Continue same dose Continue same dose Continue same dose
Increase dose Increase dose
If DBP ≥60 mmHg If DBP ≥60 mmHg
IBU 200 mg +
ISO 20 mg
15–21 22–28Days
Figure 1 Flow chart of the isOFen2 study. 
Abbreviations: iBU, ibuprofen; isO, isosorbide dinitrate; DBP, diastolic blood pressure.
Table 1 Demographic and baseline characteristics of the subjects 
of the isOFen1 study
Variable Frequency
caucasian race, n (%) 12 (100%)
Male sex, n (%) 12 (100%)
age (years) 23±2
height (m) 1.82±0.06
BMi (kg/m2) 22.61±2.58
smokers 4 (33.3%)
Medical history
– allergies 2 (acetaminophen, grass, dust mite, and 
ambrosia)
– respiratory 1 (allergic rhinitis)
– gastrointestinal 2 (inguinal hernia and an appendectomy)
– Musculoskeletal 3 (arthroscopy, fractures of long bone and 
c4–c5 vertebra, slipped disc l4–l5, l3–l4, 
l5–s1)
– allergies 2 (acetaminophen, grass, dust mite and 
ambrosia)
– respiratory 1 (allergic rhinitis)
Abbreviations: n, number; BMi, body mass index; c, cervical; l, lumbar; 
s, sacral.
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isOFen1 – pharmacokinetics
The mean plasma drug concentration–time profiles after the 
administration of ibuprofen (200 mg) given alone or in com-
bination with ISO are given in Figure 2A. The temporal phar-
macokinetic profiles of ibuprofen alone or in  combination 
with ISO were comparable. The lack of effect of ISO on 
ibuprofen exposure was also confirmed by the nonsignificant 
difference in the ibuprofen AUC
t–∞ (5.9±8.4 mg*hour/L 
versus 6.0±6.6 mg*hour/L; P=0.08). The same result was 
also confirmed by the other main pharmacokinetic parameters 
(C
max
, T
max
, t
1/2
; Table 3).
The mean plasma drug concentration–time profile after 
the administration of ISO, given alone or in combination 
with ibuprofen, are shown in Figure 2B. No significant 
differences were observed in the T
max
 and C
max
 when com-
paring ISO given alone versus ISO given concomitantly 
with ibuprofen. A significant difference was found in the 
AUC
0–t 
(1,155±201 ng*hour/mL versus 1,270±234 ng*hour/
mL; P=0.019), but not confirmed when the AUC
0–∞ was 
considered (1,478±266 ng*hour/mL versus 1,533±249 
ng*hour/mL; P=0.241; Table 3).
The lack of a mutual pharmacokinetic drug-to-drug inter-
action between ibuprofen and ISO was also confirmed when 
applying the more stringent criteria dictated by the EMA’s 
Guideline on the Investigation of Bioequivalence.35 These 
guidelines require that the 90% CIs for the ratio of the test and 
reference products are contained within the acceptance inter-
val of 0.80–1.25.35 Indeed, the ratios of the AUC
0–∞ between 
each drug when administered alone versus when combined 
with the other were 0.99 (90% CI: 0.92–1.06) and 1.06 
(90% CI: 0.98–1.14) for ibuprofen and ISO, respectively.
isOFen2 – subjects’ characteristics
Nineteen healthy Caucasian male volunteers participated in 
the ISOFEN2 study. Baseline characteristics of the enrolled 
subjects are given in Table 4. All subjects were Caucasian and 
the majority were nonsmokers. The mean age was 24±5 years, 
and the mean body mass index was 22±2 kg/m2.
isOFen2 – tolerability
All the enrolled subjects completed the study, being treated 
with the study drugs for a median of 27 days (range: 24–28 
days). Safety assessments, including hematochemical 
analyses, vital signs, and cardiac and respiratory evaluations, 
showed no differences between the beginning and the end 
of the study (Table 5).
Eighteen out of the 19 enrolled subjects tolerated the 
treatment well and completed the study, reaching the highest 
dose of ISO (80 mg/day). Only one subject voluntarily decided 
to reduce the dose of ISO from 80 mg to 60 mg. Overall, 31 
treatment-related AEs were recorded during the study, the 
large majority being episodes of headache (Table 6). Such 
episodes did not persist, and they gradually decreased in 
Table 2 Variations of the laboratory analyses and vital signs 
between the screening and the final visit (ISOFEN1)
Screening visit Final visit
creatinine (mg/dl) 0.88±0.09 0.87±0.10
Urea (mg/dl) 32±6.75 34±5.08
alT (U/l) 23±8.09 23±9.11
alP (U/l) 61±14.3 61±13.55
ggT (U/l) 22±12.79 25±13.73
WBc (103/μl) 6.18±1.77 6.41±1.30
rBc (106/μl) 5.04±0.44 5.47±1.66
Platelet (103/μl) 200±46.91 215±62.99
systolic blood pressure (mmhg) 126±6 109±3.59
Diastolic blood pressure (mmhg) 68±11 67±6.34
heart rate (bpm) 82±2 67±7.78
Note: Values are expressed as mean ± standard deviation.
Abbreviations: alT, alanine aminotransferase; alP, alkaline phosphatase; ggT, 
gamma glutamyl transpeptidase; WBc, white blood cells; rBc, red blood cells; 
n, number.
0
0
50
100
150
200
250
300
0 60 120 180 240 300 360
Time (min)
420 480 540 600 660 720
0 60 120 180 240 300 360
Time (min)
420 480 540 600 660 720
2
4
6
8
10
12
Ib
u
p
ro
fe
n
, m
g
/L
Is
o
so
rb
id
e,
 n
g
/m
L
14
16
18A
B
Ibuprofen
Ibuprofen+ISO
ISO+ibuprofen
ISO
Figure 2 Pharmacokinetic profiles of isosorbide and ibuprofen after the 
administration of isO, ibuprofen, or their combination. 
Notes: (A) Ibuprofen profile; (B) isosorbide profile representing the mean (standard 
deviation) plasma drug concentrations over time, as measured in healthy volunteers 
(n=12) given each drug alone (black circles) or in combination (white circles). 
Abbreviations: isO, isosorbide dinitrate; n, number.
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Table 3 Main isosorbide and ibuprofen pharmacokinetic parameters (following the administration of isO and ibuprofen alone or in 
combination)
Pharmacokinetic  
parameter
Isosorbide Isosorbide +  
ibuprofen
t-test Ibuprofen Ibuprofen +  
isosorbide
t-test
cmax^ 187±50 215±51 0.1375 60.2±12.8 59.4±13.5 0.7480
Tmax, minutes 65±33 65±38 0.9883 108±69 110±56 0.8106
t1/2, minutes 303±61 280±63 0.2206 172±105 177±85 0.1479
aUc0–t° 1,155±201 1,270±234 0.0197 60.2±12.8 59.4±13.5 0.7480
aUct–∞° 304±141 280±119 0.5550 5.9±8.4 6.0±6.6 0.0829
aUcextrapolated, % 20.4±7.1 18.3±6.9 0.3363 8.2±8.8 8.7±7.2 0.4691
aUc0–∞° 1,458±266 1,533±249 0.2409 66.1±14.7 65.4±15.4 0.8765
Notes: ^ng/ml for isosorbide and mg/l for ibuprofen; °ng*hour/ml for isosorbide and mg*hour/l for ibuprofen. Values are expressed as means ± standard deviation.
Abbreviations: isO, isosorbide dinitrate; cmax, maximum observed plasma drug concentration; Tmax, time at which the cmax was observed; t1/2, estimated terminal phase half-
life; aUc0–t, area under the plasma drug concentration time curve from predose to the last measurable dose; aUc0–∞, area under the concentration time curve versus the 
time curve up to infinity.
Table 4 Demographic and baseline characteristics of the subjects 
of the isOFen2 study
Variable Frequency
caucasian race, n (%) 19 (100%)
Male sex, n (%) 19 (100%)
age (years) 24±5
height (m) 1.79±0.08
Weight (kg) 72±10
BMi (kg/m2) 22±2
smokers 7 (36.84%)
Medical history
– allergies 2 (rifaximine and grass, dust mites and 
ambrosia)
– endocrine/metabolic 1 (hypothyroidism)
– Musculoskeletal 1 (medial lemniscus injury)
– Psychiatric 1 (slight anxious depressive syndrome)
Abbreviations: n, number; BMi, body mass index.
Table 5 Variations of the laboratory analyses and vital signs 
between the screening visit and the final visit (ISOFEN2)
Screening  
visit
Final visit
creatinine (mg/dl) 0.98±0.10 0.96±0.12
Urea (mg/dl) 34±7.05 34±8.73
alT (U/l) 24±10.71 23±12.04
alP (U/l) 67±22.52 64±25.05
ggT (U/l) 20±16.23 22±18.04
WBc (103/μl) 6.26±1.29 6.64±1.41
rBc (106/μl) 5.11±0.43 5.12±0.41
Platelet (103/μl) 208±50.57 211±53.20
systolic blood pressure (mmhg) 111±9.11 108±9.04
Diastolic blood pressure (mmhg) 66±4.09 64±5.84
heart rate (bpm) 67±8.98 69±8.78
Note: Values are expressed as mean ± standard deviation.
Abbreviations: alT, alanine aminotransferase; alP, alkaline phosphatase; ggT, 
gamma glutamyl transpeptidase; WBc, white blood cells; rBc, red blood cells; n, 
number.
intensity during the first week of the treatment period. Only 
one subject reported persistent, albeit tolerable, headaches 
up to the end of the study. The time course of BP variations 
determined at the different visits is graphically represented in 
Figures 3 and 4. No significant differences were observed in 
the diastolic or systolic BP measured at 0 minutes, 30  minutes, 
60 minutes, 120 minutes, and 180 minutes following drug 
administration between the different ISO dosages.
Discussion
In the ISOFEN1 study, we demonstrated that the pharma-
cokinetics of ibuprofen given alone versus ibuprofen given 
concomitantly with ISO were similar, as documented by 
the lack of statistically significant differences in the main 
drug pharmacokinetic parameters (T
max
, C
max
, AUC
0–t
, and 
AUC
0–∞). Similarly, we found that the coadministration of 
ibuprofen did not significantly affect the pharmacokinetics 
of ISO. Indeed, only a minor increase in the AUC
0–12
 of ISO 
was observed when ibuprofen was added concomitantly. 
This increase, which accounted for less than 10% of the 
daily drug exposure, was considered not clinically relevant. 
Interestingly, no significant differences were observed 
when comparing ISO alone versus the drug combination 
for the other pharmacokinetic parameters. The lack of a 
mutual pharmacokinetic drug-to-drug interaction between 
ibuprofen and ISO was confirmed also when applying the 
more stringent criteria dictated by the EMA’s Guideline on 
the Investigation of Bioequivalence.35 For the application of 
these guidelines, we considered the AUC of each drug given 
alone as the “reference” and the AUC of each drug given in 
combination as the “test” product. In every instance, we found 
that the ratio of the AUCs from zero to infinity were within 
the window of acceptance of 0.80%–1.25%.
Concerning the safety profile of the drugs given alone or 
combined, no serious AEs occurred during the study, with no 
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meaningful effects on vital signs, electrocardiograms, or 
laboratory parameters. The majority of the AEs recorded 
during the study were scored as treatment-related. In par-
ticular, all subjects experienced mild-to-moderate headache, 
remitting spontaneously in 0.5–1 hour – a known side effect 
of ISO. The results of the ISOFEN1 study confirmed the 
optimal tolerability of the combined therapy with ibuprofen 
and ISO previously documented in a pilot study in dystrophic 
patients.23 In mouse models of DMD, the effect of ISO plus 
ibuprofen is endowed with a synergistic therapeutic effect.25,26 
The similar pharmacokinetic profiles of ibuprofen and ISO, 
when given alone or combined, allow us to exclude that the 
synergism between these two drugs is eventually related to 
an unmasked pharmacokinetic drug-to-drug interaction.
The main result of the ISOFEN2 study was the definition 
of the maximum tolerated dose of ISO in combination with 
ibuprofen, and the further assessment of the safety of the 
combined treatment in terms of AEs and variations in BP. We 
found that the combination of ibuprofen (200 mg) with ISO 
(up to 80 mg/day) was well tolerated by nearly 95% of the 
subjects, thus largely exceeding the 85% cutoff fixed as the 
primary end point. No serious AEs were recorded during 
the study with respect to vital signs, electrocardiograms, 
or laboratory parameters. The majority of the AEs were 
judged as treatment-related and scored as mild to moderate 
in intensity. Also, in this study, headache was experienced at 
the highest concentrations of ISO, and it was moderate and 
remitted spontaneously within 1 hour following drug intake. 
All AEs resolved spontaneously without any concomitant 
treatment.
Table 6 Overview of adverse events recorded during the 
isOFen2 trial
Statistics
Overall incidence of aes
 number of events 34
 n of subjects (%) 15 (78.9)
Treatment-related aes
 number of events 31
 n of subjects (%) 15 (78.9)
intensity, n (%)
 Mild 31 (91.17)
 Moderate 3 (8.82)
 severe 0
episodes of headache
 number of events 28
 single episode 11
 – n of subjects (%) 8 (53.3)
 Periodic 17
 – n of subjects (%) 10 (66.6)
Abbreviations: aes, adverse events; n, number.
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Figure 3 Time course of diastolic blood pressure variations during the study. 
Notes: Diastolic blood pressure was measured at the different study visits in which isO doses were up-titrated from 20 mg to 80 mg once daily at predose and 1 hour and 
3 hours postdose. 
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In a previous study conducted in patients, the combination 
of ibuprofen (200 mg twice a day) in combination with ISO 
at 20 mg/day was found to be well tolerated.27 The results of 
the ISOFEN2 study also confirmed the optimal tolerability 
of the combined therapy when ISO is given at higher concen-
trations, up to 80 mg/day. Accordingly, it can be reasonably 
speculated that DMD patients with a poor response to the 
combined treatment at low doses (20 mg twice a day) of ISO 
may eventually benefit from progressive up-titration of drug 
doses up to 80 mg/day, provided that strict monitoring of the 
patient’s BP is performed.
The main results of the two studies (ie, the safety and 
absence of pharmacokinetic interactions) indicate that 
from a therapeutic perspective, the combination of ISO 
and ibuprofen is highly manageable. This information 
can be used to design novel studies conducted with the 
aim of evaluating the safety and efficacy of this combined 
treatment in patients affected by DMD. Several acquired 
and inherited neuromuscular disorders are associated with 
a loss of functional NO signaling and inflammation, 
including muscular dystrophies other than the Duchenne 
form and myopathies.36 The high clinical manageability 
of the combination of ISO and ibuprofen encourages 
preclinical studies to verify its beneficial effect in these 
other pathologies.
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